Prof Adam Winstock - The acceptability of psychedelics in psychiatry

Psychedelic substances, specifically LSD and psilocybin, show potential clinical advantages when compared to traditional antidepressants as first-line treatment options. Global Drug Survey data reveals that psychedelic users demonstrate deliberate planning and responsible usage patterns, effectively disproving myths of rampant abuse or widespread harm. Patient populations experiencing psychiatric conditions express significant openness toward psychedelic-assisted therapies, viewing them as favorable alternatives to conventional treatments. However, stigma remains a barrier to seeking help or discussing experiences openly. Effective integration of these substances into clinical practice relies on dispelling long-standing misinformation and fostering informed conversations about both benefits and risks.